论文部分内容阅读
目的：探讨肺癌ｐ５３基因突变与临床之关系；方法：采用ＰＣＲ－限制性片段长度多态性分析法（ＰＣＲ－ＲＦＬＰ）检测４７例人肺癌ｐ５３基因２４９位密码子点突变；结果：非小细胞肺癌（ＮＳＣＬＳ）ｐ５３基因２４９位密码子突变率２４．２４％，小细胞肺癌（ＳＣＬＣ）突变率为０（０／１４），ｐ５３基因２４９位密码子点突变与肺癌分期、组织分化、吸烟无关（Ｐ＞０．０５），与ＮＳＣＬＣ淋巴结转移有关（Ｐ＜０．０５）；结论：ｐ５３基因２４９位密码子突变是ＮＳＣＬＣ突变热点，是评估ＮＳＣＬＣ预后因素之一。
Objective: To investigate the relationship between p53 gene mutation and clinical characteristics in lung cancer. Methods: PCR-restriction fragment length polymorphism (PCR-RFLP) was used to detect the 249 codon mutation of p53 gene in human lung cancer; Results: Non-small cell The mutation rate of 249 codons in p53 gene of lung cancer (NSCLS) was 24.24%, and the mutation rate in small cell lung cancer (SCLC) was 0 (0/14). The p53 gene codon mutation at point 249 was not associated with lung cancer staging, tissue differentiation, or smoking. (P>0.05), associated with lymph node metastasis of NSCLC (P<0.05); Conclusion: The codon mutation at position 249 of p53 gene is a hotspot of NSCLC mutation and is one of the prognostic factors of NSCLC.